gemc: hematologic and oncologic emergencies: resident training
DESCRIPTION
This is a lecture by Dr. Joe Lex from the Ghana Emergency Medicine Collaborative. To download the editable version (in PPT), to access additional learning modules, or to learn more about the project, see http://openmi.ch/em-gemc. Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike-3.0 License: http://creativecommons.org/licenses/by-sa/3.0/.TRANSCRIPT
Project: Ghana Emergency Medicine Collaborative, 2013 Document Title: Hematologic and Oncologic Emergencies Author(s): Joe Lex, MD, FACEP, FAAEM, MAAEM (Temple University) License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike-3.0 License: http://creativecommons.org/licenses/by-sa/3.0/
We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. These lectures have been modified in the process of making a publicly shareable version. The citation key on the following slide provides information about how you may share and adapt this material. Copyright holders of content included in this material should contact [email protected] with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit http://open.umich.edu/privacy-and-terms-use. Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition. Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.
1
Attribution Key
for more information see: http://open.umich.edu/wiki/AttributionPolicy
Use + Share + Adapt
Make Your Own Assessment
Creative Commons – Attribution License
Creative Commons – Attribution Share Alike License
Creative Commons – Attribution Noncommercial License
Creative Commons – Attribution Noncommercial Share Alike License
GNU – Free Documentation License
Creative Commons – Zero Waiver
Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ
Public Domain – Expired: Works that are no longer protected due to an expired copyright term.
Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105)
Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain.
Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that your use of the content is Fair. To use this content you should do your own independent analysis to determine whether or not your use will be Fair.
{ Content the copyright holder, author, or law permits you to use, share and adapt. }
{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }
{ Content Open.Michigan has used under a Fair Use determination. }
2
Hematologic and Oncologic Emergencies
Joe Lex, MD, FACEP, FAAEM, MAAEM Associate Professor of Emergency Medicine,
Department of Emergency Medicine Temple University School of Medicine
Philadelphia, PA USA
3
4
Menu
• Transfusions • Bleeding disorders • Platelet disorders • Red cell disorders • White cell disorders • Oncologic emergencies
5
Questions
6
7
Who Needs Blood?
• Most patients uncomfortable if hemoglobin concentration <7 g/dL
• Patients with heart or pulmonary disease may need hemoglobin concentration of ≥10 g/dL to safeguard adequate oxygen transport
8
What’s Available?
• Packed Red Blood Cells: centrifuged whole blood with 80% of plasma removed
• Adult: 1 unit PRBC raises hemoglobin by 1 gm/dL
• Child: Each mL/kg raises hemoglobin by 1 gm/dL
9
What’s Available?
• Platelets: shelf life ~5 days – ABO / Rh checks are needed – “Six pack” raises count by ~30,000
• Fresh Frozen Plasma: ~1 year – 1 unit / mL of each coagulation factor – No cellular components – 10–15 mL / kg (3–4 250 mL bags)
10
Special Needs
• All blood products now leukocyte-depleted
• Washed cell products in patients with confirmed deficiency of IgA
• Irradiated cell products used to prevent graft-versus-host reactions in immunosuppressed patients
11
Acute Intravascular Hemolytic Transfusion Reaction
• Typically due to ABO incompatibility (clerical error)
• Intravascular lysis of donor RBCs
12
Acute Intravascular Hemolytic Transfusion Reaction
• Sudden fever, chills, headache, flushing, low back pain, nausea, tachycardia, hypotension
• Shortly after transfusion starts • Hemoglobinuria, hemoglobinemia
13
Acute Intravascular Hemolytic Transfusion Reaction
• Stop infusion • Direct Coombs on recipient’s blood
detects host antibodies • Look at plasma: if red… • Look at urine: if red…
14
Acute Intravascular Hemolytic Transfusion Reaction
• CBC, chemistries, liver panel, coagulation profile, haptoglobin, lactate dehydrogenase (LDH)
15
Acute Intravascular Hemolytic Transfusion Reaction
• Send bag to blood bank • IV fluids (new tubing) • Consider furosemide, mannitol
16
Febrile Nonhemolytic
• Multiple prior transfusions or multiparous women
• Fever, chills shortly after start • Same workup as acute
intravascular hemolytic reaction • Diagnosis of exclusion
17
Febrile Nonhemolytic
• Stop transfusion • IV fluid through new tubing • Antipyretic • Broad-spectrum antibiotic(s) • Future transfusions: probably
leukoreduced
18
Febrile Nonhemolytic
• MILD: if patient responds to antihistamine, may resume transfusion
• SEVERE: antihistamine, steroids, epinephrine, IVF
19
Massive Transfusion
• Hyperkalemia or hypokalemia • Citrate breakdown into bicarbonate è metabolic alkalosis
• Citrate / serum calcium complex è hypocalcemia
• Coagulopathy • Hypothermia from cold blood • Volume overload
20
Delayed Hemolytic
• Extravascular: antibodies react to non-ABO antigens
• Antibody-coated RBCs removed from circulation by liver and spleen before they are lysed è extravascular è no hemoglobinemia, hemoglobinuria
21
Delayed Hemolytic
• Typically asymptomatic, may have fever
• Same workup as acute intravascular hemolytic reaction
22
TRALI
• Transfusion-associated acute lung injury (TRALI)
• Increasingly recognized event • Acute respiratory distress, often
associated with fever, non-cardiogenic pulmonary edema, and hypotension
• ~1 in 2000 transfusions 23
Transfusion-Associated Graft-versus-Host Disease
• Donor lymphocytes recognize immunocompromised recipient as foreign, attack host tissues
• Usually 4–10d post transfusion • Fever, N-V, rash, diarrhea
24
Transfusion-Associated Graft-versus-Host Disease
• Same workup as acute intravascular hemolytic reaction
• No effective treatment: possibly stem cell transplant
25
Disease Transmission
• HIV: 1 in 2,000,000 • Hepatitis B: 1 in 137,000 • Hepatitis C: 1 in 1,000,000
26
Other Complications
• Hypothermia from cold blood • Volume overload • Breakdown of citrate into
bicarbonate è metabolic alkalosis • Citrate / serum calcium complex è
hypocalcemia
27
8. Your patient is profoundly anemic and you believe she would benefit from a blood transfusion. In weighing benefits against risks, you tell her that the most common adverse effect is: a. hepatitis C transmission. b. hepatitis B transmission. c. human immunodeficiency virus (HIV)
transmission. d. febrile nonhemolytic reaction. e. graft versus host reaction.
28
8. Your patient is profoundly anemic and you believe she would benefit from a blood transfusion. In weighing benefits against risks, you tell her that the most common adverse effect is: a. hepatitis C transmission. b. hepatitis B transmission. c. human immunodeficiency virus (HIV)
transmission. d. febrile nonhemolytic reaction. e. graft versus host reaction.
29
8. Most common transfusion adverse
Febrile non-hemolytic reaction is estimated to occur once for every 200 units transfused. During the transfusion or within a few hours after its completion, the patient has a temperature elevation of at least 1°C and usually has chills. The usual cause of this febrile reaction is an antigen-antibody reaction involving the plasma, platelets, or white blood cells that are passively transfused to the recipient along with the RBCs. 30
8. Most common transfusion adverse
Once a febrile transfusion reaction is recognized, the current transfusion should be terminated because there is not sufficient clinical evidence to differentiate the simple febrile nonhemolytic reaction from the more serious immediate hemolytic reaction.
31
32
Thrombus Formation
• Damaged epithelium è collagen and tissue factor (TF) exposed to flowing blood è adherence / activation of platelets (relies on von Willebrand Factor [vWF])
33
Thrombus Formation
• Tissue factor activates coagulation cascade è generates thrombin è converts fibrinogen to fibrin è forms long, cross-linking strands that trap platelets and RBCs to form insoluble clot
34
Thrombus Formation
• Thrombin also triggers tissue plasminogen activator è activates plasmin
• Plasmin, anti-thrombin III, protein C & protein S cause fibrinolysis
35
Warfarin
• Inhibits Vitamin K-dependent coagulation factors II, VII, IX, X – Half-lives 7h (FVII) to 50h (FII)
• Inhibits Vitamin K-dependent anticoagulants Protein C & S – Half-lives up to 40h
• 1st few days: may be procoaguable
36
Warfarin Overdose: No Bleed
• INR <5: omit next warfarin or ê dose
• INR 5 – 9: omit next 1-2 doses, give oral vitamin K (1 – 2.5 mg)
• INR >9: omit warfarin, give oral vitamin K (2.5 – 5 mg)
• Avoid subcutaneous vitamin K
37
Warfarin Overdose: Bleed
• Vitamin K 10 mg slow IV infusion • Fresh frozen plasma (FFP): start
with 4 – 6 units – Each ml of FFP contains 1unit of
each coagulation factor – INR will not correct beyond ~1.5
• Prothrombin complex concentrate – Rapid, expensive, procoaguability
38
Heparin Overdose
• Heparin activates antithrombin III • Short half-life: stopping drip will
normalize in few hours • Can reverse with protamine sulfate:
1mg IV for every 100u heparin unfractionated given in prior 2 hrs – Works a little for LMWH
39
Liver Disease
• Liver synthesizes nearly all clotting factors
• é PT/INR do not correlate well with risk of bleeding
• Can reverse with FFP if active bleeding, require invasive procedure
• ± vitamin K 40
41
Hemophilias
• Inherited: sex-linked recessive • Factor VIII: hemophilia A (more
common) • Factor IX: hemophilia B • Clinically indistinguishable • PTT elevated in both
42
Clinical Severity
• Related to activity level of factor <1% - severe à frequent
spontaneous bleeds 1 – 5% - moderate à occasional
spontaneous, lots in trauma >5% - mild à no spontaneous,
excessive in trauma, surgery
43
• Vast majority in ED have known disease, present with complications
• Most common: intramuscular, intra-articular bleeds
Presentation
44
Treatment: Based on Complaint
• Minor bleeding: replace 25% • Severe bleeding: replace 50% • Life-threatening: replace 100% • FVIII: 1U/kg é plasma level ~2% • FIX: 1U/kg é plasma level ~1% • In ED, assume baseline plasma
level to be zero 45
Replacement Factors
• Can be recombinant or derived from human plasma
• Hemophilia A: mild to moderate à start with DDAVP – Causes release of vWF and FVIII
from endothelial cells • Arthrocentesis rarely indicated
46
5. The initial dose of factor VIII required for a 60-kg male with severe hemophilia A in whom you suspect a ruptured spleen is:
a. 1,500 units b. 2,850 units c. 3,000 units d. 6,000 units e. 5,700 units
47
5. The initial dose of factor VIII required for a 60-kg male with severe hemophilia A in whom you suspect a ruptured spleen is:
a. 1,500 units b. 2,850 units c. 3,000 units d. 6,000 units e. 5,700 units
48
5. …initial dose of factor VIII … severe hemophilia A … ruptured spleen … 3,000 units.
A 60-kg patient with a life threatening hemorrhage who requires 100% correction will need 50 mL/kg = 3000 units of factor VIII
49
von Willebrand Disease
• Mucocutaneous bleeding more likely
• Hemarthrosis less likely • Humate F®: FVIII-vWF concentrate • DDAVP only effective in Type 1
50
15. A 38-year-old woman has von Willebrand’s disease, Type I. She complains of blood-tinged emesis and epigastric pain. Her stool tests weakly positive for blood. Appropriate initial therapy includes: a. vitamin K. b. 6 units platelet concentrate. c. factor IX concentrate. d. desmopressin (DDAVP). e. plasmapheresis.
51
15. A 38-year-old woman has von Willebrand’s disease, Type I. She complains of blood-tinged emesis and epigastric pain. Her stool tests weakly positive for blood. Appropriate initial therapy includes: a. vitamin K. b. 6 units platelet concentrate. c. factor IX concentrate. d. desmopressin (DDAVP). e. plasmapheresis.
52
15. von Willebrand’s disease, Type I ... blood-tinged emesis … initial therapy… Treatment of von Willebrand’s disease depends on the type of disease that is present and the severity of bleeding. Desmopressin (DDAVP) treatment has benefit in patients with mild to moderately severe von Willebrand’s disease, but should be given in consultation with a hematologist. Factor VIII (cryoprecipitate) or fresh frozen plasma may be used in patients with severe bleeding.
53
Disseminated Intravascular Coagulation (DIC)
• Many potential causes: infection, malignancy, trauma, OB
• Loss of hemostasis regulatory mechanisms
• Thrombin overproduced è promotes clotting
• Fibrin obstructs small vessels • Consumed platelets and factors
54
Presentation
• May be lab abnormalities only: no overt clinical signs
• Bleeding, organ dysfunction possible
55
Presentation
• CBC: thrombocytopenia, possible anemia
• Blood smear: schistocytes • PT/INR, PTT: prolonged • D-dimer/FSP: elevated • Fibrinogen: diminished
56
Treatment
• Treat underlying cause • Bleeding-predominant: FFP,
platelets, cryoprecipitate • Clotting-predominant: heparin
– More common in chronic DIC – Not appropriate for acute DIC
57
3. The most helpful lab study in diagnosing disseminated intravascular coagulation is the:
a. D-dimer, which is elevated. b. partial thromboplastin time (PTT), which
is decreased. c. fibrinogen level, which is elevated. d. prothrombin time, which is prolonged. e. fibrin degradation products (FDP), which
are diminished. 58
3. The most helpful lab study in diagnosing disseminated intravascular coagulation is the:
a. D-dimer, which is elevated. b. partial thromboplastin time (PTT), which
is decreased. c. fibrinogen level, which is elevated. d. prothrombin time, which is prolonged. e. fibrin degradation products (FDP), which
are diminished. 59
3. Useful labs in DIC
MOST USEFUL: • PT / INR – é • Platelet count – usually ê • Fibrinogen level – ê HELPFUL: • aPTT – usually é • Thrombin clot time – é • Fragmented RBCs – present • FDP and D-dimers – é
60
10. The cornerstone of Emergency Department management of DIC is: a. hemodynamic stabilization and
treatment of the underlying disorder. b. rapid correction of thrombocytopenia. c. aggressive resuscitation with colloid. d. pan-culture and broad-spectrum
antibiotic coverage. e. rapid intubation and hyperventilation.
61
10. The cornerstone of Emergency Department management of DIC is: a. hemodynamic stabilization and
treatment of the underlying disorder.
b. rapid correction of thrombocytopenia. c. aggressive resuscitation with colloid. d. pan-culture and broad-spectrum
antibiotic coverage. e. rapid intubation and hyperventilation.
62
10. Cornerstone of managing DIC The primary cause of the DIC needs to be determined and treated. The high mortality rate in severe DIC is primarily due to the underlying disorder. Many patients with DIC require no specific therapy if there is no evidence of bleeding, or if thrombosis and laboratory studies are not deteriorating. The first principle of management is to stabilize the patient hemodynamically, providing oxygen, fluids, and life support as needed.
63
64
Platelet Disorders
ê platelets = thrombocytopenia 1. ê production 2. Splenic sequestration 3. é destruction: drugs, infection,
DIC, ITP, TTP 4. Dilution: massive blood
transfusion 65
Platelets
• Platelet life-span: 10 days • Each day marrow produces /
releases ~10% of platelets • Platelet count <20,000:
spontaneous bleed • Platelet count >50,000: minimal
needed to avoid bleeding in trauma / surgery
66
Platelets
• Aspirin blocks COX receptors for life of platelet
• Withhold aspirin for 1 day è ~25,000 active platelets
• Withhold aspirin for 2 days è ~50,000 active platelets
• NSAIDs block COX receptors for life of NSAID (~4 – 8 hours)
67
Thrombotic Thrombocytopenic Purpura (TTP)
Classic Pentad in 40% 1. Microangiopathic hemolysis 2. Thrombocytopenia 3. Neurologic symptoms 4. Fever 5. Renal dysfunction (usually mild)
68
Thrombotic Thrombocytopenic Purpura (TTP)
More Common Triad in 75% 1. Microangiopathic hemolysis 2. Thrombocytopenic purpura 3. Neurologic symptoms
69
Presentation
• More common in women, adults in 4th decade of life
• 40% have URI / flu-like symptoms prior to presentation
• Fatigue, malaise • Fever • Neurologic symptoms: headache,
confusion, seizure, stroke, coma 70
Diagnosis
• Peripheral blood: schistocytes • CBC: anemia, thrombocytopenia • LDH: markedly é (ischemia,
hemolysis) • Creatinine: é • Urine: blood, protein, casts • PT/PTT typically normal
71
Treatment
• Plasma exchange: very effective • Platelet transfusion CONTRA-
INDICATED (é thrombus formation)
• Last resort: steroids, splenectomy
72
6. A 44-year-old woman with a history of TTP, in remission for 30 days, presents to the ED complaining of lethargy. Laboratory results would likely show:
a. é LDH, é reticulocyte count, é red blood cell count.
b. é LDH, é reticulocyte count, é creatinine.
c. ê platelet count, ê red blood cell count, ê reticulocyte count.
d. ê platelet count, ê reticulocyte count, ê LDH.
73
6. A 44-year-old woman with a history of TTP, in remission for 30 days, presents to the ED complaining of lethargy. Laboratory results would likely show:
a. é LDH, é reticulocyte count, é red blood cell count.
b. LDH, reticulocyte count, creatinine.
c. ê platelet count, ê red blood cell count, ê reticulocyte count.
d. ê platelet count, ê reticulocyte count, ê LDH.
74
6. TTP – Laboratory results
In TTP, laboratory studies will show an anemia of variable degree, LDH, reticulocytosis, indirect bilirubin, negative Coombs’ test, and schistocytes on peripheral smear. Thrombocytopenia is often severe with the count <20,000/mL in 50% of patients. BUN and creatinine are typically .
75
Hemolytic Uremic Syndrome (HUS)
• Similar to TTP, but worse renal dysfunction, less severe neurologic symptoms – ~60% require hemodialysis
• “Typical” or “childhood”: follows acute bloody diarrhea – Most common: E coli O157:H7 – Usually 5 years and younger
76
Treatment
• Plasma exchange not as effective as with TTP
• Avoid platelet transfusions as with TTP
77
1. A patient with anemia, thrombocytopenia, renal failure, normal coagulation tests and a clear sensorium probably has:
a. idiopathic thrombocytopenic anemia. b. thrombotic thrombocytopenic purpura. c. hemolytic-uremic syndrome. d. disseminated intravascular coagulation. e. autoimmune hemolytic anemia.
78
1. A patient with anemia, thrombocytopenia, renal failure, normal coagulation tests and a clear sensorium probably has:
a. idiopathic thrombocytopenic anemia. b. thrombotic thrombocytopenic purpura. c. hemolytic-uremic syndrome. d. disseminated intravascular coagulation. e. autoimmune hemolytic anemia.
79
1. Hemolytic Uremic Syndrome
ITP generally presents with isolated thrombocytopenia. TTP causes neurologic symptoms in addition to the other symptoms. DIC will have abnormal coagulation studies. Autoimmune hemolytic anemia may cause severe rapid anemia, which may present with angina or congestive heart failure.
80
4. Hemolytic-uremic syndrome is most commonly seen in:
a. neonates. b. infants and children 6 months to 4
years of age . c. adolescents. d. women age 30 to 50. e. both sexes, over age 75.
81
4. Hemolytic-uremic syndrome is most commonly seen in:
a. neonates. b. infants and children 6 months to
4 years of age. c. adolescents. d. women age 30 to 50. e. both sexes, over age 75.
82
4. Hemolytic-uremic syndrome is most commonly seen in infants and children.
Hemolytic-uremic syndrome (HUS) is a disease mainly of infancy and early childhood, with a peak incidence between 6 months and 4 years of age.
83
• More common with unfractionated • Heparin-dependent antibody
activates platelets • Signs / symptoms occur 5 to 7 days
after starting heparin • ~50% develop thrombosis
– Venous or arterial – Life- and limb-threatening
Heparin-Induced Thrombocytopenia (HIT)
84
• Moderate thrombocytopenia (~50% reduction)
• HIT antibodies in serum • Discontinue all heparins, avoid in
future • Avoid warfarin: can progress to
gangrene • Other medicines can also cause
Diagnosis & Treatment
85
11. Heparin-induced thrombocytopenia:
a. does not occur with low molecular weight heparins.
b. requires a minimum number of units, so a heparin “flush” is always safe.
c. can paradoxically cause thrombosis, ischemia, and amputation.
d. never occurs during the first 24 hours of infusion.
e. is easily treated with warfarin and fresh-frozen plasma.
86
11. Heparin-induced thrombocytopenia:
a. does not occur with low molecular weight heparins.
b. requires a minimum number of units, so a heparin “flush” is always safe.
c. can paradoxically cause thrombosis, ischemia, and amputation.
d. never occurs during the first 24 hours of infusion.
e. is easily treated with warfarin and fresh-frozen plasma.
87
11. HIT thrombosis
Heparin-induced thrombocytopenia (HIT) is due to an antibody, usually IgG, which attaches to and stimulates platelets. This platelet activation produces both thrombocytopenia and a tendency for thrombosis. The incidence of HIT is between 1 and 3% in patients treated with unfractionated heparin but significantly less in patients treated with LMW products.
88
11. HIT thrombosis
The onset of HIT is usually 5 to 12 days after heparin treatment is started but may be sooner for patients who developed the antibody from a previous exposure. Thrombosis may involve the skin (similar to warfarin-induced cutaneous necrosis), the arteries (e.g., femoral artery thrombosis), or the veins (e.g., recurrent DVT or PE).
89
• Acute in children (age 2 – 6) – Viral prodrome – Self-limited: remission in 90% – Treatment: supportive
• Chronic form: adult females
Idiopathic (Autoimmune) Thrombocytopenic Purpura (ITP)
90
• Easy bruising, prolonged menses, mucosal bleeding
• Petechiae, purpura • Diagnosis: thrombocytopenia on
CBC
Signs and Symptoms
91
• Steroids (?) • If refractory: splenectomy or
immunosuppressive therapy • Platelet transfusion ONLY if serious
bleeding • Intravenous immunoglobulin G
(IVIG) in children with intracranial hemorrhage (rare)
Treatment
92
14. A 5-year-old girl complains of weakness and fatigue. Two weeks ago she saw her family doctor and was diagnosed with an upper respiratory infection. She received no medicine at that time. Physical examination shows only a scattered petechial rash located in areas where her clothing is snug against her skin, such as underwear elastic lines. Laboratory studies show a white blood cell count 11,000/mm3 , Hgb 10.5 mg/dL, and platelet count of 16,000/mm3. Appropriate management of this patient should be: 93
14. Recent URI … petechial rash … platelet count of 16,000/mm3.
a. platelet concentrate transfusion. b. discharge home with instructions to
limit contact sports. c. admit for salicylate therapy. d. admit for splenectomy. e. admit for observation.
94
14. Recent URI … petechial rash … platelet count of 16,000/mm3.
a. platelet concentrate transfusion. b. discharge home with instructions to
limit contact sports. c. admit for salicylate therapy. d. admit for splenectomy. e. admit for observation.
95
14. Recent URI … petechial rash … platelet count of 16,000/mm3.
Acute idiopathic thrombocytopenic purpura (ITP) is seen most often in children 2 to 6 years old. A viral prodrome is common, usually within 3 weeks of the onset. The platelet count falls, usually to <20,000/mm3. The course is self-limited, with a greater than 90% rate of spontaneous remission. Morbidity and mortality are low. Treatment is supportive. Steroid therapy does not alter disease course.
96
97
• Lymphadenopathy: mostly above diaphragm (lower neck, subclavicular)
• Large mediastinal mass è chest pressure, cough, dyspnea
• B symptoms: weight loss, fever, night sweats – May be presenting complaint
Lymphoma: Hodgkin
98
• Diagnosis: lymph node biopsy showing Reed-Sternberg cells
• Treatment: chemotherapy / radiation
Lymphoma: Hodgkin
99
• Proliferation of lymphoid cells from lymph nodes OR lymphatic tissue other than bone marrow
• B-Cell, T-Cell, NK-Cell: can be indolent or aggressive
• Diagnosis: biopsy • Treatment: chemotherapy /
radiation
Non-Hodgkin Lymphoma
100
• Anemia + thrombocytopenia + neutropenia
• Bone marrow diseases: myelo-dysplasia, myelofibrosis, some leukemias and lymphomas
• Systemic diseases: lupus, severe infection, sarcoidosis, alcohol, tuberculosis, êvitamin B12, folate
Pancytopenia
101
102
• Pancytopenia with hypocellular bone marrow – Acquired: marrow stem cells
damaged by drugs, radiation, virus, chemical, immune-related
– Inherited: Fanconi’s anemia, dyskeratosis congenita
Aplastic Anemia
103
• Bleeding, easy bruising • Fatigue, malaise, anemia è short
of breath • Infection common
Signs & Symptoms
104
• CBC, reticulocyte count • Bone marrow biopsy • Immediate: depends on severity of
anemia / thrombocytopenia / neutropenia ± complications
• Bone marrow transplant
Diagnosis / Treatment
105
Red Blood Cells (RBC)
• Normal life: ~120 days • Marrow releases ~1% total count
daily – “baby red cells” = nucleated =
reticulocytes
106
7. The most helpful laboratory study to differentiate poor red blood cell production from increased red cell destruction is the:
a. sedimentation rate. b. sideroblast level. c. serum iron level. d. total to direct bilirubin ratio. e. reticulocyte count.
107
7. The most helpful laboratory study to differentiate poor red blood cell production from increased red cell destruction is the:
a. sedimentation rate. b. sideroblast level. c. serum iron level. d. total to direct bilirubin ratio. e. reticulocyte count.
108
7. ê production vs destruction
Reticulocytes are RBCs of intermediate maturity. They are an index of the production of mature RBCs by the bone marrow (reported as a percent of total RBCs). ê reticulocyte count reflects impaired RBC production; seen with low levels of iron, vitamin B12, folate, bone marrow failure. reticulocyte count reflects accelerated erythropoeisis, the normal marrow response to anemia; seen with blood loss and hemolytic anemias. 109
Aplastic Anemia
• Normal MCV with ê reticulocyte • Can be RBC aplasia alone
110
Sickle Cell Disease
• Inherited mutated hemoglobin: HbS • Recessive gene: both parents need
to pass to offspring • HbS + HbA: trait è asymptomatic • HbS + HbC (beta-thalassemia):
chronic anemia + recurrent painful crises
111
Sickle Cell Disease
• RBC life span 10 – 15 days • Marrow on constant “overdrive” • Reticulocyte “normal” 8 – 10% • WBC “normal” at 15 – 20K • Hemoglobin “normal” at 8 – 10 • Platelets “normal” >500K
112
Vaso-Occlusive Crisis
• AKA acute painful episode • Pain in extremities, chest,
abdomen, back • No lab test can confirm • No vital sign can confirm • Treatment: analgesia
– Avoid meperidine
113
Acute Chest Syndrome
• New infiltrate on chest x-ray + fever, cough, ésputum, dyspnea, tachypnea, hypoxia
• Many causes: fat embolism from marrow ischemia, pulmonary vaso-occlusion, infection, venous thromboembolism, pulmonary edema
114
Acute Chest Syndrome
• Children: fever & cough most common
• Adults: fever & chest pain as presenting complaint – Some develop 2 – 3 days into
hospital stay • ± hypoxemia
115
Acute Chest Syndrome
• Chest x-ray normal in ~50% • Treatment supportive • Empiric antibiotic: 3rd / 4th
generation cephalosporin + macrolide
• Severe è exchange transfusion
116
Splenic Sequestration
• Etiology: unknown • Typically occurs in infants
– Tender, enlarged spleen – Signs of hypovolemia, shock – Concurrent infection common
• Diagnosis: worsening anemia, persistent reticulocytisis, tender large spleen
117
Splenic Sequestration
• Treatment: – Intravenous fluids – Blood transfusion – May need splenectomy after acute
episode resolves
118
Aplastic Crisis
• Marrow shuts down • Abrupt ê hemoglobin • Abrupt ê reticulocytes (<2%) • Causes: folate deficiency, human
parvovirus B19 (in children) • Blood transfusion: severe anemia,
cardiorespiratory symptoms
119
Hemolytic Crisis
• Abrupt ê hemoglobin • Major increase reticulocyte
production • May see worsening jaundice
120
Other Complications
• Functional asplenia: infected by encapsulated organisms
• Strokes: CNS occlusive events • Priapism: low-flow due to corpora
cavernosa occlusion
121
2. The viral agent implicated in an aplastic crisis of patients with sickle cell disease is:
a. adenovirus (atypical). b. herpes simplex. c. parvovirus. d. coxsackie virus. e. HTLV-IV.
122
2. The viral agent implicated in an aplastic crisis of patients with sickle cell disease is:
a. adenovirus (atypical). b. herpes simplex. c. parvovirus. d. coxsackie virus. e. HTLV-IV.
123
2. Parvovirus & Sickle cell
Aplastic crises can be precipitated by viral infections (particularly parvovirus B19), folic acid deficiency, or the ingestion of bone marrow toxins such as phenylbutazone. Bone marrow erythropoiesis is slowed or stopped. The hematocrit falls to as low as 10%, and the reticulocyte count falls to as low as 0.5%. The white blood cell count and platelet counts usually remain stable. 124
9. A 12-year-old girl with sickle cell disease is brought by her mother after she passed out twice. She was kept home from school the last few days for a “cold.” When you ask the child to stand, you must catch her to prevent her from falling to the ground. This is suspicious for: a. salmonella sepsis. b. sequestration crisis. c. acute chest syndrome. d. aplastic crisis. e. hemolytic crisis.
125
9. A 12-year-old girl with sickle cell disease is brought by her mother after she passed out twice. She was kept home from school the last few days for a “cold.” When you ask the child to stand, you must catch her to prevent her from falling to the ground. This is suspicious for: a. salmonella sepsis. b. sequestration crisis. c. acute chest syndrome. d. aplastic crisis. e. hemolytic crisis.
126
9. Sequestration crisis
Sequestration crisis occurs primarily in children and is the second most common cause of death in children with SCD under the age of 5 years. Often preceded by viral infections, sickled cells block the splenic outflow, causing pooling of peripheral blood and sickled cells in the spleen. Such patients present in hypovolemic shock with an enlarged spleen.
127
Hemolytic Anemia
• RBC destruction • Intravascular
– Smear à fragmented RBCs (schistocytes)
– More acute than extravascular • Extravascular
– Occurs in liver or spleen – Smear à spherocytes
128
Hemolytic Anemia
• Intrinsic – Enzyme defect (G6PD, pyruvate
kinase), abnormal membrane, abnormal cell (sickle cell disease, thalassemia)
– G6PD triggered by drugs (aspirin, antimalarials, sulfa, nitrofurantoin, phenazopyridine), foods (fava beans), infection
129
Hemolytic Anemia
• Extrinsic – Autoimmune – Non-immune: HUS/TTP, HELLP,
prosthetic valve abnormality, arterio-venous malformation, malaria, drugs, spider /snake venom
130
Signs & Symptoms
• Vary depending on disease • Symptoms related to anemia • Jaundice • Hepatosplenomegaly
131
Diagnosis
• Smear à schisto-, spherocytes • Reticulocytes should be é • Haptoglobin: binds free Hgbà ê • Bilirubin é • LDH é (released from RBCs) • Hemoglobinemia, hemoglobinuria • Autoimmune è direct Coombs +
132
Hypochromic Microcytic Anemia
• ê iron à iron deficiency • ê globin à thalassemia • ê porphyrin à sideroblastic, lead
toxicity • Chronic disease
133
13. A healthy 12-year-old African-American female complains of weakness and fatigue 3 days after starting a course of trimethoprim-sulfamethoxasole and pyridium for a urinary tract infection. Her hemoglobin is 4.8 mg/dl, and her urine is tea-colored, but you see no red blood cells on microscopic exam. She probably has undiagnosed:
134
13. 12-year-old African-American female…weakness and fatigue… TMP/SMZ … hgb 4.8 mg/dl … no RBCs in urine. Undiagnosed: a. hemolytic uremic syndrome. b. G6PD deficiency. c. idiopathic thrombocytopenic purpura. d. thrombotic thrombocytopenic
purpura. e. sickle cell disease.
135
13. 12-year-old African-American female…weakness and fatigue… TMP/SMZ … hgb 4.8 mg/dl … no RBCs in urine. Undiagnosed: a. hemolytic uremic syndrome. b. G6PD deficiency. c. idiopathic thrombocytopenic purpura. d. thrombotic thrombocytopenic
purpura. e. sickle cell disease.
136
13. G6PD Deficiency of the RBC enzyme glucose-6-phosphate dehydrogenase (G-6-PD) is the most common human enzyme defect, affecting nearly one-tenth of the world’s population. The RBC is unable to protect itself against oxidant stress. Acute hemolytic crises occur that are incited by bacterial and viral infections, exposure to oxidant drugs, metabolic acidosis (such as diabetic ketoacidosis), and ingestion of fava beans in some patients.
137
13. G6PD Within 1 to 3 days following oxidant stress, the patient can develop hemoglobinuria and the potential for vascular collapse. These hemolytic crises are generally well tolerated and self-limited because only the older RBCs will hemolyze. The drugs most commonly associated with oxidant stress are sulfa drugs, antimalarials, phenazopyridine, and nitrofurantoin.
138
Diagnosis / Treatment
• ê serum iron level • ê serum ferritin level • é total iron binding capacity (TIBC) • Treatment: iron supplements,
outpatient workup
139
Macrocytic Anemia
• Most important: megaloblastic • ê folate (green vegetables, fruit,
cereals) or ê vitamin B12 (meat) è impaired DNA synthesis
140
Macrocytic Anemia
• Petechiae, mucosal bleeding, infections, sore mouth / tongue, diarrhea, weight loss
• B12 can also have paresthesias, ataxia
• Diagnosis: send levels • Treatment: replace
141
Polycythemia
• éHct: >51% in M, >48% in F • Apparent: ê plasma volume • Secondary
– Appropriate: hypoxia – Inappropriate: é erythropoietin
• Polycythemia vera: é production RBCs, WBCs, platelets – Can progress to myelofibrosis,
leukemia 142
Signs & Symptoms
• Headache, weakness, pruritus, dizziness, ésweating, visual changes, paresthesias, weight loss, joint pain
• Ruddy complexion, éspleen, éliver, éblood pressure
• Thrombosis: ACS, CVA, PE, etc • Hemorrhage
143
Diagnosis / Treatment
• éRBCs, éWBCs, éplatelets • Confirmed by non-ED studies • Treatment: phlebotomy
144
16. A 68-year-old man complains of headache, dizziness, and blurred vision. His blood pressure is 190/118 mmHg. He has a florid face, normal fundi, and marked splenomegaly. His hematocrit is 67%. Reasonable therapy includes:
145
16. … florid face … splenomegaly … hematocrit = 67%. Therapy:
a. 250cc salt-poor albumin. b. intravenous nitroprusside. c. phlebotomy. d. plasmapheresis. e. sublingual nifedipine.
146
16. … florid face … splenomegaly … hematocrit = 67%. Therapy:
a. 250cc salt-poor albumin. b. intravenous nitroprusside. c. phlebotomy. d. plasmapheresis. e. sublingual nifedipine.
147
16. … florid face … splenomegaly … hematocrit = 67%. Therapy:
Emergency treatment of any form of symptomatic polycythemia is phlebotomy. Usually not more than 500 ml of blood is slowly removed as the volume is replaced with a comparable amount of normal saline.
148
Methemoglobinemia
• éproduction or êreduction • Causes discussed in toxicology • Cyanosis with normal oxygen
saturation • Treatment:
– Congenital: usually none – Toxic è symptomatic è treat with
intravenous methylene blue
149
150
Leukemia
• éproduction undifferentiated hematopoietic stem cells
• Acute Lymphocytic (ALL) • Signs & symptoms: protean
– Related to abnormal cells crowding out normal cells à êRBC, êWBC, êplatelets
– Bacterial infections in 1/3 at time of diagnosis
151
Leukemia
• Chronic Lymphocytic (CLL): most common in patients >50 years
• Often no symptoms: may have fatigue, large lymph nodes, infections (esp. respiratory)
• Diagnosis: absolute lymphocyte count >5000 cells/ml
• Treatment: monitor, chemo 152
Multiple Myeloma
• Abnormal éplasma cells • Fatigue from anemia • Bone pain from osteolytic lesions or
pathologic fractures • Diagnosis: écalcium, écreatinine • Bone marrow: >10% plasma cells • Serum / urine protein electro-
phoresis (SPEP, UPEP) 153
Treatment
• Chemotherapy • Plasmapheresis for hyperviscosity
syndrome • If comatose: temporize by removing
1 liter blood, replace with normal saline
• écalcium: IV saline, steroids
154
155
Malignancy Complications
• Hyperviscosity syndrome • Leukostasis (sludging) • Neutropenic fever • Spinal cord compressions • Superior vena cava syndrome • Tumor lysis syndrome • Hypercalcemia • Pericardial effusion / tamponade
156
Hyperviscosity Syndrome
• éabnormal serum proteins • Waldenstrom macroglobulinemia • Multiple myeloma (less common) • Most common symptoms:
neurologic, visual • May see mucosal or GI bleeding • CHF from é plasma volume • Plasmapheresis, exchange
157
Leukostasis
• WBC sludging in microcirculation • Usually acute leukemia • Can be seen with chronic, NHL • Neurologic symptoms • Can see respiratory failure • Treatment: leukapheresis,
hydroxyurea, chemotherapy
158
Neutropenic Fever
• Absolute neutrophil count (ANC) = neutrophils + bands
• ANC <500 cells/ml • Signs and symptoms: fever • Treatment: IV antibiotics
– Ceftazidime or cefepime ± amino-glycoside or –penem
– Add vancomycin if appropriate
159
Spinal Cord Compression
• Lymphoma, metastasis, primary • S&S: back pain, weakness,
numbness, bowel / bladder / sexual dysfunction
• Diagnosis: MRI – CT myelogram if MRI not available
• Treatment – Dexamethasone – Radiation therapy
160
Superior Vena Cava Syndrome
• Tumor obstructs SVC è venous hypertension, congestion
• Early signs: face edema that improves through day
• SOB, cough, chest pain • Distension of chest, neck veins • Cyanosis • Diagnosis: chest CT • Treatment: radiation therapy
161
Acute Tumor Lysis Syndrome
• Usually after chemotherapy • Lysed cells è metabolic changes • Hyperuricemia: N/V, renal failure
due to renal precipitation • Hyperphosphatemia: N/V, lethargy,
seizures, renal impair – Also binds with Ca+ à êcalcium
• Hypocalcemia: tetany, arrhythmia 162
Acute Tumor Lysis Syndrome
• Hyperkalemia: N/V, muscle weakness, cramps, arrhythmias, heart block è asystole
• Acute renal failure: possible hemodialysis; do NOT alkalinize urine, worsens éphosphorus and êcalcium
163
Others
• Hypercalcemia: see Endocrine-Metabolic Emergencies
• Pericardial Effusion / Tamponade: see Cardiovascular Emergencies
164
12. A 42-year-old woman with adult T-cell lymphoma-leukemia complains of back pain, abdominal pain, and confusion. Laboratory evaluation shows a total calcium of 15.8 mg/dl. Appropriate management of this patient should include: a. plasmapheresis. b. IV bicarbonate. c. IV hypertonic saline / oral
Kayexalate®. d. IV normal saline and IV furosemide. e. glucagon.
165
12. A 42-year-old woman with adult T-cell lymphoma-leukemia complains of back pain, abdominal pain, and confusion. Laboratory evaluation shows a total calcium of 15.8 mg/dl. Appropriate management of this patient should include: a. plasmapheresis. b. IV bicarbonate. c. IV hypertonic saline / oral Kayexalate®. d. IV normal saline and IV
furosemide. e. glucagon.
166
12. Hypercalcemia of malignancy
Patients with severe hypercalcemia (>14 mg/dl) require immediate treatment regardless of symptoms. The four basic goals of therapy are
(1) restore intravascular volume, (2) enhance renal calcium elimination (3) reduce osteoclastic activity (4) treat primary disorder.
167
12. Hypercalcemia of malignancy
Isotonic saline is the first step. Once volume is restored, the calcium will usually have ê by 1.6 to 2.4 mg/dl, but hydration alone rarely leads to complete normalization. Loop diuretics inhibit resorption of calcium in the thick ascending loop of Henle, é the calciuric effect of hydration. Volume expansion must precede administration of furosemide, because the drug’s effect depends on the delivery of calcium to the distal nephron. 168
Pearls
• The first step in managing any transfusion reaction to to stop the transfusion
• Hemarthrosis in hemophiliacs: factor replacement, never arthrocentesis
• Minor head injury in hemophilia: replace factor, head CT, admit for observation
169
Pearls
• Initial treatment in mild-moderate hemophilia A: DDAVP
• NO PLATELET TRANSFUSION in patients with TTP, HUS
• Once a patient has HIT, no heparin can ever again be used, including LMWH
170
Thank You
171